Pillar Biosciences partners with LSI Medience for lung cancer screening
Diagnostics developer Pillar Biosciences validated its liquid biopsy test with LSI Medience on 20 August 2026 to support clinical trial screening across Asia
Pillar Biosciences and LSI Medience have partnered for a lung cancer screening project called LC-SCRUM-Asia in Japan. The collaboration aims to screen blood-based samples from 2,000 patients over two years using Pillar's oncoReveal Essential+ assay. This assay has been validated at LSI Medience for detecting circulating cell-free DNA and RNA in lung cancer patients, providing accurate and accessible liquid biopsy solutions for genomic analysis.
The project supports precision oncology research and aims to identify genomic alterations relevant to the project's objectives.
Brief written by urgent.news from Vietnam Investment Review's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
